Evidence map›Paper›PMID 41301202›Full record

ArticleBioengineering (Basel, Switzerland)2025

Preclinical Mechanistic Evaluation of Hyaluronan/Niacinamide (Vitamin B3) Hydrogels: Toward an Enhanced Viscosupplement System with Ancillary Anti-Arthritic Attributes.

Farid Hadjab, Stivens Antoine, Béatrice Hamel, Mohamed Benderdour, Hassan Fahmi, Alexandre Porcello, Virginie Philippe, Robin Martin, Cíntia Marques, Kelly Lourenço and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Farid HadjabDevelopment Department, Albomed GmbH, D-90592 Schwarzenbruck, Germany.
Stivens AntoineLaboratoire de Recherche en Orthopédie, Centre de Biomédecine, Hôpital du Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada.
Béatrice HamelLaboratoire de Recherche en Orthopédie, Centre de Biomédecine, Hôpital du Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada.
Mohamed BenderdourLaboratoire de Recherche en Orthopédie, Centre de Biomédecine, Hôpital du Sacré-Cœur de Montréal, Montreal, QC H4J 1C5, Canada.
Hassan FahmiOsteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Montreal, QC H2X 0A9, Canada.
Alexandre PorcelloDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.ORCID 0000-0003-1603-2704
Virginie PhilippeRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0003-3544-0383
Robin MartinOrthopedics and Traumatology Unit, Lausanne University Hospital, University of Lausanne, CH-1011 Lausanne, Switzerland.
Cíntia MarquesDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.
Kelly LourençoDevelopment Department, LOUNA REGENERATIVE SA, CH-1207 Geneva, Switzerland.
Corinne ScalettaRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0002-7682-9160
Nathalie Hirt-BurriRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0003-1220-0213
Philippe Abdel-SayedRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0002-6054-0573
Lee Ann ApplegateRegenerative Therapy Unit, Lausanne University Hospital, University of Lausanne, CH-1066 Epalinges, Switzerland.ORCID 0000-0002-7346-9921
Alexis E LaurentManufacturing Department, TEC-PHARMA SA, CH-1038 Bercher, Switzerland.ORCID 0000-0001-5738-8702

Funding

Albomed ALB-CA001-23
6 · The paper itself

Abstract

Osteoarthritis (OA), a degenerative joint disease primarily affecting the hips and knees, is characterized by multifactorial dysregulation of chondrocyte homeostasis and currently lacks curative treatment options. Intra-articular hyaluronic acid (HA) injections have clinically provided symptomatic relief for three decades; however, HA's rapid in vivo degradation by free radicals and hyaluronidases limits its efficacy. We hypothesized that adding niacinamide (vitamin B3) to linear HA hydrogels would provide ancillary anti-inflammatory and anti-catabolic properties, thereby improving HA-based viscosupplementation therapy. This preliminary preclinical mechanistic study investigated the functional effects of incorporating niacinamide into linear HA-based hydrogels using in vitro cellular models. Initially, Raw 264.7 macrophages and C28/I2 or SW1353 human chondrocytes were pre-treated with varying concentrations of HA/B3, with or without lipopolysaccharide (LPS) or interleukin-1β (IL-1β), respectively. Subsequently, pro-inflammatory and pro-catabolic markers were quantified biochemically. Results demonstrated that HA/B3 hydrogels exhibited enhanced functional stability compared to HA alone and possessed significant anti-inflammatory and anti-catabolic properties, without inducing cytotoxicity in either cell line. In Raw 264.7 macrophages, HA/B3 inhibited LPS-induced tumor necrosis factor-α (TNF-α) release and suppressed cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) protein expression. In vitro, HA/B3 hydrogels reduced IL-1β-induced IL-6 production in primary chondrocytes by 16% and suppressed PGE

Indexed as

antioxidantsbiophysical propertiesdegradationhyaluronic acidhydrogelsinflammationniacinamideosteoarthritisprimary chondrocytesviscosupplements

Identifiers

PMID41301202
PMCPMC12649763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.